Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

被引：12
|
作者：
Kalac, Matko [1 ,2 ,11 ]
Jain, Salvia [3 ]
Tam, Constantine S. [4 ,5 ]
Xiao, Zhengrui [6 ]
Montanari, Francesca [7 ]
Kanakry, Jennifer [8 ]
Huber, Bryan D. [9 ]
Goldfinger, Mendel [6 ]
O'Connor, Owen A.
Marchi, Enrica [10 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Hematol & Oncol, New York, NY USA
[2] Univ Calif Irvine, Dept Hematol & Oncol, Irvine, CA USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[4] Monash Univ, Melbourne, Vic, Australia
[5] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia
[6] Albert Einstein Coll Med, Dept Med, New York, NY USA
[7] Yale Univ Canc Ctr, Dept Hematol, Greenwich, CT USA
[8] NCI, Expt Transplantat & Immunotherapy Branch, NIH, Bethesda, MD USA
[9] Intermt Med Grp, Blood & Marrow Transplant Acute Leukemia Program, Salt Lake City, UT USA
[10] Univ Virginia Canc Ctr, Div Hematol & Oncol, Charlottesville, VA USA
[11] Univ Calif Irvine, Tisch Canc Inst, 200 S Manchester Ave, Orange, CA 92868 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 14期
关键词：
MUTATIONS; TET2;
D O I：
10.1182/bloodadvances.2022009445
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：3760 / 3763
页数：4
相关论文
共 50 条
  • [21] Romidepsin Treatment in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review and Meta-Analysis
    Abdulsattar, Waleed
    Beran, Azizullah
    Alqahtani, Ali
    Abuhelwa, Ziad
    Mhanna, Mohammed
    Alloghbi, Abdurahman
    Srour, Omar
    Ayesh, Hazem
    Hamouda, Danae
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (05) : E589 - E592
  • [22] Romidepsin for Cutaneous T-cell Lymphoma
    Prince, H. Miles
    Dickinson, Michael
    CLINICAL CANCER RESEARCH, 2012, 18 (13) : 3509 - 3515
  • [23] Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
    Ellin, Fredrik
    Landstrom, Jenny
    Jerkeman, Mats
    Relander, Thomas
    BLOOD, 2014, 124 (10) : 1570 - 1577
  • [24] Romidepsin for cutaneous T-cell lymphoma
    Prince, H. Miles
    Dickinson, Michael
    Khot, Amit
    FUTURE ONCOLOGY, 2013, 9 (12) : 1819 - 1827
  • [25] REAL-WORLD COSTS OF FRONT-LINE TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA IN FRANCE, GERMANY, AND THE UNITED KINGDOM
    Ashaye, A.
    Shah, R.
    Corman, S.
    Dalal, M. R.
    Fox, C.
    Trumper, L.
    VALUE IN HEALTH, 2021, 24 : S30 - S30
  • [26] ROMIDEPSIN EXPERIENCE IN 317 PATIENTS WITH T-CELL LYMPHOMAS
    Coiffier, B.
    Horwitz, S.
    Whittaker, S.
    Pro, B.
    Robak, T.
    Samtsov, A.
    Kim, Y.
    Prince, M.
    Foss, F.
    Piekarz, R.
    Nichols, J.
    Bates, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 238 - 238
  • [27] Romidepsin: A New Drug for the Treatment of Cutaneous T-Cell Lymphoma
    Frye, Robin
    Myers, Mary
    Axelrod, Karen C.
    Ness, Elizabeth A.
    Piekarz, Richard L.
    Bates, Susan E.
    Booher, Susan
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2012, 16 (02) : 195 - 204
  • [28] Comparison of hospital costs in peripheral t-cell lymphoma patients treated with pralatrexate or romidepsin.
    Gilmore, James W.
    Belk, Kathy
    Craver, Christopher W.
    McGuire, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Real-world study and prognostic analysis of angioimmunoblastic T-cell lymphoma
    Li, Suxiao
    Feng, Xiaoyan
    Song, Yunfei
    Fan, Mengke
    Chen, Qingjiang
    Zhang, Mingzhi
    Wu, Xiaolong
    Dong, Meng
    Zhang, Jieming
    Han, Lijuan
    Zhang, Xudong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [30] Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
    Foss F.
    Coiffier B.
    Horwitz S.
    Pro B.
    Prince H.M.
    Sokol L.
    Greenwood M.
    Lerner A.
    Caballero D.
    Baran E.
    Kim E.
    Nichols J.
    Balser B.
    Wolfson J.
    Whittaker S.
    Biomarker Research, 2 (1)
12345